Influence of interstitial lung disease on outcome in systemic sclerosis: A population-based historical cohort study

Chest

Volumn 144, Issue 2, 2013, Pages 571-577

  Bauer, Philippe R ^a   Schiavo, Dante N ^a   Osborn, Thomas G ^a   Levin, David L ^a   Sauver, Jennifer St ^a   Hanson, Andrew C ^a   Schroeder, Darrell R ^a   Ryu, Jay H ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; IMMUNOSUPPRESSIVE AGENT; OXYGEN;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HEART FAILURE; HIGH RISK PATIENT; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SURVIVAL TIME; SYSTEMIC SCLEROSIS; UNITED STATES;

EID: 84881531904     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-2768     Document Type: Article

References (34)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009; 360 (19): 1989-2003.
2. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classifi cation of systemic sclerosis (scleroderma). Arthritis Rheum. 1980; 23 (5): 581-590.
3. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am. 2003; 29 (2): 239-254.
4. Chiffl ot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum. 2008; 37 (4): 223-235.
5. Steen VD, Oddis CV, Conte CG, Janoski J, Casterline GZ, Medsger TA Jr. Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospitaldiagnosed cases, 1963-1982. Arthritis Rheum. 1997; 40 (3): 441-445.
6. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003; 48 (8): 2246-2255.
7. Ferri C, Valentini G, Cozzi F, et al; Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002; 81 (2): 139-153.
8. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007; 66 (7): 940-944.
9. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010; 69 (10): 1809-1815.
10. Ryu JH, Daniels CE, Hartman TE, Yi ES. Diagnosis of interstitial lung diseases. Mayo Clin Proc. 2007; 82 (8): 976-986.
11. Guillevin L, Mouthon L. Pulmonary involvement in systemic scleroderma [in French]. Bull Acad Natl Med. 2011; 195 (1): 79-90.
12. Renzoni EA. Interstitial lung disease in systemic sclerosis. Monaldi Arch Chest Dis. 2007; 67 (4): 217-228.
13. D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fi fty-eight autopsy cases and fi fty-eight matched controls. Am J Med. 1969; 46 (3): 428-440.
14. Highland KB, Silver RM. New developments in scleroderma interstitial lung disease. Curr Opin Rheumatol. 2005; 17 (6): 737-745.
15. McNearney TA, Reveille JD, Fischbach M, et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum. 2007; 57 (2): 318-326.
16. Assassi S, Sharif R, Lasky RE, et al; GENISOS Study Group. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther. 2010; 12 (5): R166.
17. Kane GC, Varga J, Conant EF, Spirn PW, Jimenez S, Fish JE. Lung involvement in systemic sclerosis (scleroderma): relation to classifi cation based on extent of skin involvement or autoantibody status. Respir Med. 1996; 90 (4): 223-230.
18. Chang B, Wigley FM, White B, Wise RA. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol. 2003; 30 (11): 2398-2405.
19. Benan M, Hande I, Gul O. The natural course of progressive systemic sclerosis patients with interstitial lung involvement. Clin Rheumatol. 2007; 26 (3): 349-354.
20. Fischer A, Swigris JJ, Groshong SD, et al. Clinically signifi cant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest. 2008; 134 (3): 601-605.
21. Melton LJ III. History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996; 71 (3): 266-274.
22. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classifi cation, subsets and pathogenesis. J Rheumatol. 1988; 15 (2): 202-205.
23. Hachulla E, Launay D. Diagnosis and classifi cation of systemic sclerosis. Clin Rev Allergy Immunol. 2011; 40(2): 78-83.
24. Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular fi ltration rate. Ann Intern Med. 2009; 150 (9): 604-612.
25. Fadem SZ, Rosenthal B. CKD-EPI & MDRD study equation calculator-(with SI units). Nephron Information Center website. http://nephron.org/MDRD-GFR.cgi. Accessed July 12, 2012.
26. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadatadriven methodology and workfl ow process for providing translational research informatics support. J Biomed Inform. 2009; 42 (2): 377-381.
27. Bergstralh EJ, Offord KP, Chu CP, Beard CM, O'Fallon WM. Calculating incidence, prevalence and mortality rates for Olmsted County, Minnesota residents: An update. Technical Report Series No. 49. Rochester, MN: Section of Biostatistics, Mayo Clinic; January 1992.
28. Good IJ. Some statistical applications of Poisson's work. Stat Sci. 1986; 1 (2): 157-170.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Sta Assoc. 1958; 53 (282): 457-481.
30. Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health. 1999; 20: 145-157.
31. Kurland LT, Hauser WA, Ferguson RH, Holley KE. Epidemiologic features of diffuse connective tissue disorders in Rochester, Minn., 1951 through 1967, with special reference to systemic lupus erythematosus. Mayo Clin Proc. 1969; 44(9): 649-663.
32. Michet CJ Jr, McKenna CH, Elveback LR, Kaslow RA, Kurland LT. Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1985; 60 (2): 105-113.
33. Lo Monaco A, Bruschi M, La Corte R, Volpinari S, Trotta F. Epidemiology of systemic sclerosis in a district of northern Italy. Clin Exp Rheumatol. 2011; 29 (2 s uppl 65): S10-S14.
34. Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum. 2010; 39 (4): 269-277.